@article{discovery10206194,
           month = {March},
           title = {Primary efficacy endpoints in phase 3 non-inferiority trials to establish new tuberculosis treatment regimens should only include microbiological outcomes},
            note = {Copyright {\copyright} 2025 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/
4.0/).},
            year = {2025},
       publisher = {Elsevier BV},
         journal = {The Lancet Microbe},
          author = {Yates, Tom A and Grint, Daniel J},
             url = {https://doi.org/10.1016/j.lanmic.2025.101117},
            issn = {2666-5247}
}